Insights

The real cost of MS infusion therapy and how a better member experience can bring down costs

aVrzVnNYClf9oxJK Leap MS image

For two years, Maria drove two hours each way for her multiple sclerosis (MS) treatment. Every appointment meant a full day away from work, on top of the drive itself. When her infusions moved to her home, that changed. "I was able to take a nap while receiving my infusion," she said. 

That's a big win for her. But it’s also a win for employers too. Every one of those infusions is a new claim. MS treatment claims can be among the largest and least transparent line items on the health plan. 

The same change that gave her a day back is the change that gave her employer a clearer bill that’s free of expensive markups on an already expensive drug. 

What is multiple sclerosis (MS)? 

MS is an immune-driven disease in which the body attacks the myelin that insulates nerve fibers in the brain and spinal cord, scarring the nervous system and disrupting the signals between brain and body.

That damage shows up as vision loss, numbness, weakness, balance and coordination problems, and fatigue. When left untreated, MS progressively disables, and many patients lose the ability to walk and become dependent on a cane, walker, or wheelchair. It is the most common disabling neurological disease of young adults, and there is no cure. 

Effective therapy matters as a way to help MS patients manage symptoms and slow the progress of the disease, which can help protect a patient's long-term mobility and independence.

What is multiple sclerosis?

The hard dollar costs of MS care

Nearly one million Americans are living with multiple sclerosis. Symptoms of MS usually start between the ages of 20 and 40, when many employees are still in the early stages of their careers. 

A National MS Society-funded analysis published in Neurology put the total US economic burden of MS at approximately $85.4 billion in a single year. At the member level, medical costs for those living with MS average $65,000 more each year when compared with those who don’t have MS. 

Disease-modifying therapies (DMTs) are a major contributor to MS-related medical costs. Examples include: 

  • IV infusion therapies: Ocrevus, Tysabri, Briumvi, and Lemtrada. Rituxan is also used off-label to treat MS.
  • Self-administered injectable therapies: Kesimpta, Copaxone/Glatopa, Avonex, Rebif, Betaseron, and Plegridy.

Oral DMTs are another major treatment category.

These infusion therapies are significant cost drivers for employers, too. Employer healthcare costs are expected to increase by their highest rate in over 20 years. Within that trend is specialty medicine, where just 1-2% of an employer’s population can be responsible for 10-15% of total healthcare costs because of the cost of care. 

Single doses (or encounters) of infusion therapies to treat MS are expensive. However, there are other factors that make costs more expensive and unpredictable for employers. 

How markups affect MS infusion and injectable costs

An employer might assume that an $89,000 claim for a 600mg Ocrevus encounter in a hospital outpatient (HOPD) setting reflects the cost of the drug. But it doesn’t. And the lack of transparency around what drives that cost can make it challenging to solve for. 

These drugs are often being procured in HOPDs through a buy-and-bill model. In this model: 

  1. A hospital or clinic purchases the drug.
  2. The cost of the drug can be marked up by as much as 400%. 
  3. The drug is administered to the patient. 
  4. The claim is submitted in a single, unbundled J-Code. 

The employer often only sees one amount if they dig into their J-Codes. But how much was the cost of the drug versus the administration fee versus the provider margin? 

An employer has two significant needs: More transparency and no markups. 

How much does a dose of Ocrevus actually cost?

Prices fluctuate, but the cost of a single dose of Ocrevus is often much less once the markup is removed. 

With the 600mg Ocrevus example, Leap may acquire the dose at $35,000, keeping in mind that prices can fluctuate somewhat from dose to dose. Leap then bills the whole encounter through three clear line items: 

  • The drug’s true acquisition cost (free of any markup), which would be $35,000.
  • Care coordination fee provided by one of our Care Guides. In this case, let’s say it’s $5,000.
  • Clinical administration of the drug by a nurse. We’ll place this number at $1,000.

All told, that same encounter of Ocrevus would run about $41,000, which is a 54% reduction from the $89,000 encounter in an HOPD setting. The drug’s dosage didn’t get cheaper. It’’s just that the markup was eliminated and care was shifted outside of a hospital setting, which is typically more expensive. 

This same methodology can apply to other infusion therapies, such as Tysabri or Briumvi. 

jnhQyg043OevnoA0 Leapvs.currentprovidersavings 4962%C3%972439 savings comparison chart 4962x2439 image

MS care’s impact on presenteeism and absenteeism 

MS patients face a number of unique challenges adhering to care in a hospital setting. And those challenges impact them and their employers. For example: 

  • Fatigue is one of the most common MS symptoms, and a half-day round trip to an infusion center is the type of activity that can worsen fatigue. 
  • Balance and coordination problems can also make a crowded hospital parking structure or a long hallway walk harder than it needs to be. 

Employees with relapsing-remitting MS report absenteeism and presenteeism at roughly two and 1.8 times the rate of employees who don’t have MS, respectively. Some of that could be driven by symptoms, but some of it could also be driven by the care itself. 

Matt's story is the concrete version of that pattern. For two years before he started care with Leap, he and his family made a four-hour round trip to an infusion clinic in New Orleans every six months for his Ocrevus treatment, losing a full workday each time. Every hospital visit an MS patient makes is a missed-workday risk layered on top of the drug cost itself. 

This also provides a real incentive for employers (beyond avoiding drug markups) to find other options for their employees with MS to receive care. 

Is it safe to perform MS infusions and injections in the home? 

Yes, and the research on home infusion consistently points that way. A systematic review of home infusion studies found that patients who received infusions at home were no more likely to experience adverse drug events or side effects than patients treated in other settings. Their clinical outcomes were as good or better, and patients strongly preferred home care.

Research specific to Ocrevus supports the same conclusion. In a pilot study published by the National Home Infusion Association, Sofia Shrestha, now senior director of clinical strategy at Leap, and her colleagues compared Ocrevus infusion reactions among MS patients treated in a hospital with those treated at home or in an ambulatory infusion suite. Reaction rates, severity, and management were similar across settings, and no IV line infections were reported at any site.

Home infusion of biologics has been done safely for decades. Leap partners with licensed RNs who have infusion or ICU backgrounds, are trained to manage IV therapy, and know how to recognize a reaction early.

4 ways that Leap can improve the experience

Four things happen at once when an MS patient moves to Leap:

  1. The markup disappears. Leap sources every drug at true acquisition cost and bills it separately from care coordination and clinical administration, so there's no hidden margin riding on top of the drug price. 
  2. Care moves out of the highest-cost setting. Home infusion, or a Leap Transparency Network clinic when that's the better clinical fit, avoids the facility fees baked into a hospital outpatient bill.
  3. Members stay on schedule. A dedicated Care Guide handles prior authorization, prescriber coordination, and scheduling, which helps avoid the gaps and delays that can lead to a missed or postponed dose, the same gaps that put a patient's long-term disease control at risk.
  4. Members get the workday back. Evening and weekend home appointments mean a member isn't burning a full day of PTO every four weeks or every six months just to receive treatment.

Would you like a closer look at how much you could save with Leap? Request an impact analysis today.

Share this post

More insights

4fgyyvwF4RbiP1Ge Photo05%E2%80%94nursecheckingtheIVsite leap 05 nurse checking iv site 4962x2439 image
Infusion care

Is home infusion right for every patient? Here’s who decides

When patients learn they can receive their infusions at home, they might reasonably ask: Can I start...

Read article
uGsQNuRFuKAhTzKX benefits leader a reviewing report image
Education

Your guide to J-codes in medical billing, and what they can hide

An employer’s specialty trend was running at double digits, driven largely by therapies like Ocrevus...

Read article
gr 7yJaj1xLjiPDQ inside nurseadjustingIVdripforseniorpatientathome image
Education

Want to increase member participation in a specialty medicine solution? Reducing or waiving cost share is a good start.

One employee at a self-funded employer received Gammagard infusions twice a month for a rare autoimm...

Read article
A2LILi0roy6lnpj7 task export 6 image
Education

6 specialty medicine trends for 2027 and what they mean for benefits leaders

If it feels like specialty medicine is changing faster than your benefits strategy can keep up, that...

Read article
qmQqiddpjKSpw85s HRprofessional%E2%80%94intheoffice hr professional 3 office image
Education

Healthcare point solutions: What they are and 5 questions when evaluating them

If every healthcare point solution delivered the return in its sales deck, employer health costs wou...

Read article
XC0BuEWYGds6rfBI WeInfusepartnershipbloggraphic PNG%2C4962%C3%972439%2C300PPI 1 image
News

Leap expands specialty infusion network with WeInfuse collaboration

Leap is expanding its employer specialty infusion network through a new collaboration with WeInfuse,...

Read article
mIVvKbrIeVcspajE Spring Fall couplesittingtogetherongardenbenchwithcoffee image
Insights

Infusion vs. injection: Breaking down the basics of these two specialty therapies

In 1995, there were about 30 specialty drugs on the market. Today, there are nearly 1,000, and rough...

Read article
EJGfZMLy5m1bnieu inside closeupivdripformingdropletinhospital image
Insights

Let's blow up the buy-and-bill drug model: How it works and what it costs employers

Twice a year, a member with multiple sclerosis (MS) sits down for an Ocrevus infusion. The drug is t...

Read article
Oncology biosimilars market
Education

The emerging oncology biosimilars market and how employers can prepare.

A member who starts Keytruda today will likely organize the next two years of their life around it. ...

Read article
WWqCZQJnAGmcLNW4 Summer couplesittingtogetheronporchswing image
Education

Is home infusion safe for immunoglobulin therapy? What patients should know

Whether you've just been prescribed immunoglobulin (Ig) therapy, or you've been getting it at a clin...

Read article